Jun. 25 at 11:11 AM
$FOLD Amicus announces approval of Pombiliti + Opfolda in Japan
Amicus Therapeutics announced that Japan's Ministry of Health, Labour and Welfare, MHLW, has approved Pombiliti + Opfolda for the treatment of adult patients with late-onset Pompe disease, LOPD. "We are delighted that we will now be able to offer a compelling new treatment option to patients living with late-onset Pompe disease in Japan. We are grateful to the MHLW and to Japan's Pompe community, including the patients, families, and physicians who participated in our clinical studies, for their collaboration," said Bradley Campbell, President and Chief Executive Officer, Amicus Therapeutics, Inc.